Dr. Sabrina Paganoni, Massachusetts General Hospital, reviews CENTAUR, a new trial for people with ALS. CENTAUR ("Combination of Phenylbutyrate and Tauroursodeoxycholic Acid") is a Phase 2 trial that will test the efficacy and safety of AMX0035 for the treatment of ALS. It will also test the impact of AMX0035 on several disease biomarker and provide insights into ALS disease biology. CENTAUR will enroll 132 participants nationwide.
